Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
CAL-51 | Neratinib | EGFR/HER2 | RTK | 2.2484 | 0.2802 | 0.0910 | 0.0109 | 1.5163 | 4.6402 | 0.98601 |
CAL-85-1 | Alpelisib | PI3Ka | PI3K/mTOR | 3.6425 | 0.2928 | 0.1938 | 0.0110 | 0.4506 | 41.7026 | 0.9641 |
HCC1143 | ABT-737 | Bcl2/XL | Misc | 6.1992 | 0.3758 | 0.1027 | 0.0110 | 0.8672 | 8.5825 | 0.98522 |
HME1 | Palbociclib | CDK4/6 | Cell cycle | 0.22285 | 0.2572 | 0.2611 | 0.0111 | 0.9777 | 0.10881 | 0.98803 |
T47D | Ipatasertib | AKT | PI3K/mTOR | 0.13653 | 0.1331 | 0.4303 | 0.0112 | 1.0853 | 0.10541 | 0.99474 |
PDX1258 | Olaparib | PARP | Misc | 11.9912 | 0.5770 | 0.0287 | 0.0113 | 1.2287 | 29.2905 | 0.94883 |
MCF7 | Trametinib | MEK | MAPK/nRTK | Inf | 0.5581 | 0.2767 | 0.0114 | 1.2083 | 0.0027903 | 0.99413 |
SK-BR-3 | Cisplatin | Chemo | Chemotherapy | 5.1075 | 0.2490 | 0.0978 | 0.0114 | 1.4151 | 5.7965 | 0.99044 |
MDA-MB-157 | Alpelisib | PI3Ka | PI3K/mTOR | 9.7515 | 0.4924 | 0.1041 | 0.0114 | 0.6775 | 11.4208 | 0.96993 |
MCF7 | ABT-737 | Bcl2/XL | Misc | 22.5968 | 0.7267 | 0.0146 | 0.0115 | 1.1080 | 29.1513 | 0.88699 |
MDA-MB-468 | Cabozantinib | VEGFR2/MET | RTK | 8.9681 | 0.4233 | 0.0441 | 0.0115 | 1.7711 | 16.6732 | 0.9812 |
SUM1315MO2 | Palbociclib | CDK4/6 | Cell cycle | 0.093193 | 0.3001 | 0.3314 | 0.0115 | 0.9738 | 0.030153 | 0.98295 |
MDA-MB-436 | Ipatasertib | AKT | PI3K/mTOR | 25.8679 | 0.6111 | 0.1038 | 0.0116 | 0.4073 | 383.9431 | 0.92516 |
HCC1500 | Alpelisib | PI3Ka | PI3K/mTOR | 12.7881 | 0.5807 | 0.0302 | 0.0118 | 1.1251 | 18.7215 | 0.91512 |
MDA-MB-157 | Saracatinib | SRC | MAPK/nRTK | 5.2322 | 0.3548 | 0.1697 | 0.0119 | 0.4524 | 59.3534 | 0.96508 |
MDA-MB-231 | Pictilisib | pan PI3K | PI3K/mTOR | 5.3159 | 0.3053 | 0.2062 | 0.0120 | 0.3649 | 107.9707 | 0.87205 |
PDX1258 | Ipatasertib | AKT | PI3K/mTOR | 4.4024 | 0.3985 | 0.1556 | 0.0120 | 0.7553 | 1.2185 | 0.94717 |
HCC70 | A-1210477 | Mcl-1 | Misc | Inf | 0.9380 | 0.0054 | 0.0123 | 0.0000 | Inf | 0.17964 |
HCC1419 | Cediranib | VEGFR/cKIT | RTK | 5.0599 | -0.0329 | 0.0545 | 0.0124 | 4.9952 | 5.1984 | 0.99032 |
MDA-MB-436 | Pictilisib | pan PI3K | PI3K/mTOR | 5.2741 | 0.2850 | 0.1328 | 0.0124 | 0.7767 | 21.6999 | 0.98441 |
CAL-51 | Trametinib | MEK | MAPK/nRTK | Inf | 0.7064 | 0.0662 | 0.0124 | 0.8944 | 0.19105 | 0.98439 |
HCC1395 | TGX221 | PI3Kb | PI3K/mTOR | 8.4625 | 0.4581 | 0.0950 | 0.0125 | 0.6815 | 16.0341 | 0.94431 |
SUM149PT | Abemaciclib | CDK4/6 | Cell cycle | 0.6361 | 0.0949 | 0.3411 | 0.0126 | 0.4432 | 1.358 | 0.96302 |
HCC1419 | Saracatinib | SRC | MAPK/nRTK | 0.91888 | -0.1146 | 0.2758 | 0.0128 | 0.8021 | 1.8388 | 0.98394 |
HCC1500 | Cabozantinib | VEGFR2/MET | RTK | 4.6683 | 0.1837 | 0.0599 | 0.0128 | 4.9992 | 4.2912 | 0.97044 |